Research Topics
| Malcolm MaclureSummaryAffiliation: University of Victoria Country: Canada Publications
| Collaborators
|
Detail Information
Publications
Drug insurance utilization management policies and "reference pricing": an illustrated commentary on the article by Vittorio Maio and colleaguesMalcolm Maclure
School of Health Information Science, University of Victoria, B.C. V8W 3P5, Canada
Milbank Q 83:131-47. 2005
Camouflaged sampling and contacting of people from administrative databases: reaching target patients without knowing who they areMalcolm Maclure
School of Health Information Science, Faculty of Human and Social Development, University of Victoria, Victoria, BC, Canada
Pharmacoepidemiol Drug Saf 17:790-7. 2008..Methods are needed for using confidential data to select and reach patients without compromising their health privacy...
Designed delays versus rigorous pragmatic trials: lower carat gold standards can produce relevant drug evaluationsMalcolm Maclure
School of Health Information Science, University of Victoria, Victoria, British Columbia, Canada
Med Care 45:S44-9. 2007..Centralized administrative databases enable low-cost pragmatic randomized trials (PRTs) of drug effectiveness and safety. We simplified the PRT strategy by using designed delays (DD) to evaluate drug policies...- A case study examining the impacts of conferencing technologies in distributed healthcare groupsMowafa Househ
Northern Health Authority, Riyadh, Kingdom of Saudi Arabia
Healthc Q 12:112-5. 2009..In this paper, we describe key lessons learned from a two-year case study (2004-2006) on the impacts of conferencing technologies on social interaction norms within knowledge exchange groups... - Using administrative healthcare data to recruit study subjects: experience with 'camouflaged sampling'Larry D Lynd
Department of Health Care and Epidemiology, Faculty of Medicine University of British Columbia, Centre for Health Evaluation and Outcomes Sciences, Vancouver, BC, Canada
Eur J Epidemiol 19:517-25. 2004..To recruit a sample of asthmatics heterogeneous for short-acting (SA) beta-agonist use while protecting their privacy, and to compare participants recruited via 'camouflaged sampling' to those recruited through media advertising... - When should case-only designs be used for safety monitoring of medical products?Malcolm Maclure
Department Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, Canada
Pharmacoepidemiol Drug Saf 21:50-61. 2012..To assess case-only designs for surveillance with administrative databases... - Measuring prescribing improvements in pragmatic trials of educational tools for general practitionersMalcolm Maclure
School of Health Information Science, Faculty of Human and Social Development, University of Victoria, British Columbia BC, Canada
Basic Clin Pharmacol Toxicol 98:243-52. 2006..A decade of progress on methods for evaluating prescribing improvement programs with drug claims data has enabled planning of routine randomized pragmatic trials of education and policies in primary care in Canada... - 'Why me?' versus 'why now?'--differences between operational hypotheses in case-control versus case-crossover studiesMalcolm Maclure
School of Health Information Science, University of Victoria, Victoria, British Columbia, Canada
Pharmacoepidemiol Drug Saf 16:850-3. 2007 - Influence of relative age on diagnosis and treatment of attention-deficit/hyperactivity disorder in childrenRichard L Morrow
Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Victoria, BC
CMAJ 184:755-62. 2012..We sought to determine the influence of relative age within a grade on the diagnosis and pharmacologic treatment of attention-deficit/hyperactivity disorder (ADHD) in children... - Information system support as a critical success factor for chronic disease management: Necessary but not sufficientCarolyn J Green
School of Health Information Science, University of Victoria, Victoria, BC, Canada
Int J Med Inform 75:818-28. 2006..Improvement of chronic disease management in primary care entails monitoring indicators of quality over time and across patients and practices. Informatics tools are needed, yet implementing them remains challenging... - Case-crossover designs compared with dynamic follow-up designsMalcolm Maclure
Pharmaceutical Services Division, British Columbia Ministry of Health, Victoria, BC, Canada
Epidemiology 19:176-8. 2008 - Impact of two sequential drug cost-sharing policies on the use of inhaled medications in older patients with chronic obstructive pulmonary disease or asthmaColin R Dormuth
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
Clin Ther 28:964-78; discussion 962-3. 2006..Evaluations of drug cost-sharing policies within the same population are needed for a fair comparison of different options... - A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequencesSebastian Schneeweiss
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120, USA
Clin Pharmacol Ther 79:379-88. 2006..We evaluated the clinical and economic consequences of coverage restriction for 3 leading proton pump inhibitors (PPIs) in a large-scale natural experiment... - Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experimentSebastian Schneeweiss
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont St, Suite 3030, Boston, MA 02120, USA
Circulation 115:2128-35. 2007.... - Consistency of performance ranking of comorbidity adjustment scores in Canadian and U.S. utilization dataSebastian Schneeweiss
Division of Pharmacoepidemiology and Pharmacoeconomics, Gigham and Women s Hospital and Harvard Medical School, Boston, MA 02120, USA
J Gen Intern Med 19:444-50. 2004..We sought to evaluate and rank the performance of comorbidity scores across selected U.S. and Canadian elderly populations using health care utilization databases... - Physician gender and changes in drug prescribing after the implementation of reference pricing in British ColumbiaMargreet S Duetz
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
Clin Ther 25:273-84. 2003..However, these differences are unlikely to have meaningful clinical or economic consequences... - Effect of periodic letters on evidence-based drug therapy on prescribing behaviour: a randomized trialColin R Dormuth
Therapeutics Initiative, University of British Columbia, Vancouver
CMAJ 171:1057-61. 2004..We sought to measure the impact of a series of evidence-based drug therapy letters mailed to physicians in British Columbia on prescribing to newly treated patients... - Prescription duration after drug copay changes in older people: methodological aspectsSebastian Schneeweiss
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, 221 Longwood Ave, Boston, MA 02115, USA
J Am Geriatr Soc 50:521-5. 2002..Reference pricing, a copayment for expensive medications above a fixed limit, for angiotensin-converting enzyme(ACE) inhibitors in older British Columbia residents, is used as a case example... - Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilizationSebastian Schneeweiss
Department of Epidemiology, Harvard School of Public Health, Boston, Mass, USA
CMAJ 166:737-45. 2002..The objective of this study was to analyze the effect of reference-based pricing of angiotensin-converting enzyme (ACE) inhibitors on drug utilization, cost savings and potential substitution with other medication classes... - Does knowledge of medication prices predict physicians' support for cost effective prescribing policiesJennifer M Polinski
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Boston, MA, USA
Can J Clin Pharmacol 15:e286-94. 2008..Years after implementation, these policies remain controversial among physicians... - Emergency hospital admissions after income-based deductibles and prescription copayments in older users of inhaled medicationsColin R Dormuth
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
Clin Ther 30:1038-50. 2008..Objective: The aim of this study was to compare the effects of 2 recent cost-sharing policies on emergency hospitalizations due to chronic obstructive pulmonary disease, asthma, or emphysema (CAE), and on physician visits... - Quasi-experimental longitudinal designs to evaluate drug benefit policy changes with low policy complianceSebastian Schneeweiss
Divison of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 221 Longwood Ave BLI 341, Boston, MA 02115, USA
J Clin Epidemiol 55:833-41. 2002..Results from nonrandomized comparisons of subgroups defined by their compliance to a policy change should generally be interpreted cautiously, and several biases should be explored... - The impact of cost sharing on antidepressant use among older adults in British ColumbiaPhilip S Wang
National Institute of Mental Health, Bethesda, MD 20892 9629, USA
Psychiatr Serv 59:377-83. 2008.... - Commitment to change statements can predict actual change in practiceJacqueline Wakefield
Education and Research Services, Foundation for Medical Practice Education, McMaster University, 1280 Main St. West, DTC Basement, Hamilton, ON L8S 4L8
J Contin Educ Health Prof 23:81-93. 2003..The percentage of physicians who did change their prescribing varied significantly by condition. Further study of the process of translating commitment to change into real practice change is needed... - Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial resultsSebastian Schneeweiss
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
Med Care 45:S131-42. 2007..The goal of restricting study populations is to make patients more homogeneous regarding potential confounding factors and treatment effects and thereby achieve less biased effect estimates... - Adherence to beta-blocker therapy under drug cost-sharing in patients with and without acute myocardial infarctionSebastian Schneeweiss
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont St Ste 3030, Boston, MA 02120, USA
Am J Manag Care 13:445-52. 2007.... - Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockersSebastian Schneeweiss
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, Boston, Mass 02120, USA
Clin Pharmacol Ther 74:388-400. 2003.... - The effects of coxib formulary restrictions on analgesic use and cost: regional evidence from CanadaDeborah A Marshall
Centre for Evaluation of Medicines, 105 Main Street East, Level P1, Hamilton, ON L8N 1G6, Canada
Health Policy 84:1-13. 2007..Ontario required physicians to submit the clinical indications for their use on the prescription. British Columbia required physicians to seek and receive prior authorisation from the drug plan... - Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluationsSebastian Schneeweiss
Brigham and Women s Hospital and Harvard Medical School, Division of Pharmacoepidemiology and Pharmacoeconomics, 1620 Tremont St Suite 3030, Boston, MA 02120, USA
BMJ 328:560. 2004..To compare the results of a randomised and an observational evaluation of the same policy that restricted reimbursement for nebulised respiratory medications in adult patients in a community setting... - Net health plan savings from reference pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residentsSebastian Schneeweiss
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02120, USA
Med Care 42:653-60. 2004..Critics argued that drug plan savings are offset by administrative costs and increased spending on other health services... - Better Prescribing Project: a randomized controlled trial of the impact of case-based educational modules and personal prescribing feedback on prescribing for hypertension in primary careCarol P Herbert
University of Western Ontario, Faculty of Medicine and Dentistry, Health Sciences Addition, London, Ontario N6A 5C1, Canada
Fam Pract 21:575-81. 2004..The purpose of this study was to assess the impacts of individualized prescribing feedback and interactive small group education aimed at encouraging evidence-based prescribing in family/general practice... - Outcomes of reference pricing for angiotensin-converting-enzyme inhibitorsSebastian Schneeweiss
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
N Engl J Med 346:822-9. 2002..Although reference pricing may reduce the costs of prescription drugs, there is concern that patients may switch to less effective medications or stop treatment...